Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Mar;39(3):775–777. doi: 10.1128/AAC.39.3.775

SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.

N C Karyotakis 1, M C Dignani 1, E J Anaissie 1
PMCID: PMC162625  PMID: 7793892

Abstract

Candida krusei is increasingly recognized as an opportunistic pathogen in immunocompromised patients and is inherently resistant to fluconazole. We tested the in vivo efficacy of SCH 51048, an investigational antifungal triazole, in experimental hematogenous murine infection caused by two C. krusei isolates and compared its activity with those of amphotericin B and fluconazole. CF1 mice were immunosuppressed with cyclophosphamide and cortisone acetate and were challenged intravenously with infecting inocula of each C. krusei isolate. Treatment with SCH 51048 (50 or 100 mg/kg of body weight per day orally) or amphotericin B (2 mg/kg/day intraperitoneally) significantly prolonged the survival of infected mice and significantly reduced fungal titers in the kidneys (P < or = 0.05). Treatment with fluconazole (100 mg/kg/day orally) had no effect. Both dosages of SCH 51048 were as effective as amphotericin B in improving survival, but the higher dosage was significantly (P < or = 0.05) better in reducing the fungal burden in the kidneys of infected animals. A dose-dependent response was observed with SCH 51048 treatment, especially in organ clearance. Our results indicate that SCH 51048 is the first triazole that has in vivo activity against experimental infection with C. krusei and deserves further evaluation.

Full Text

The Full Text of this article is available as a PDF (161.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anaissie E. J., Karyotakis N. C., Hachem R., Dignani M. C., Rex J. H., Paetznick V. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis. 1994 Aug;170(2):384–389. doi: 10.1093/infdis/170.2.384. [DOI] [PubMed] [Google Scholar]
  2. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S43–S53. doi: 10.1093/clinids/14.supplement_1.s43. [DOI] [PubMed] [Google Scholar]
  3. Anaissie E., Paetznick V., Bodey G. P. Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother. 1991 Aug;35(8):1641–1646. doi: 10.1128/aac.35.8.1641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chandrasekar P. H., Gatny C. M. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. J Antimicrob Chemother. 1994 Feb;33(2):309–318. doi: 10.1093/jac/33.2.309. [DOI] [PubMed] [Google Scholar]
  5. Fisher M. A., Shen S. H., Haddad J., Tarry W. F. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother. 1989 Sep;33(9):1443–1446. doi: 10.1128/aac.33.9.1443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goodman J. L., Winston D. J., Greenfield R. A., Chandrasekar P. H., Fox B., Kaizer H., Shadduck R. K., Shea T. C., Stiff P., Friedman D. J. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992 Mar 26;326(13):845–851. doi: 10.1056/NEJM199203263261301. [DOI] [PubMed] [Google Scholar]
  7. Karyotakis N. C., Anaissie E. J., Hachem R., Dignani M. C., Samonis G. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J Infect Dis. 1993 Nov;168(5):1311–1313. doi: 10.1093/infdis/168.5.1311. [DOI] [PubMed] [Google Scholar]
  8. McQuillen D. P., Zingman B. S., Meunier F., Levitz S. M. Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. Clin Infect Dis. 1992 Feb;14(2):472–478. doi: 10.1093/clinids/14.2.472. [DOI] [PubMed] [Google Scholar]
  9. Merz W. G., Karp J. E., Schron D., Saral R. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol. 1986 Oct;24(4):581–584. doi: 10.1128/jcm.24.4.581-584.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Meunier F., Aoun M., Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S120–S125. doi: 10.1093/clinids/14.supplement_1.s120. [DOI] [PubMed] [Google Scholar]
  11. Morace G., Manzara S., Dettori G. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole. Chemotherapy. 1991;37(1):23–31. doi: 10.1159/000238828. [DOI] [PubMed] [Google Scholar]
  12. Odds F. C. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother. 1993 Apr;31(4):463–471. doi: 10.1093/jac/31.4.463. [DOI] [PubMed] [Google Scholar]
  13. Viviani M. A., Tortorano A. M., Malaspina C., Colledan M., Paone G., Rossi G., Bordone G., Pagano A. Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis. Eur J Epidemiol. 1992 May;8(3):433–436. doi: 10.1007/BF00158579. [DOI] [PubMed] [Google Scholar]
  14. Wingard J. R., Merz W. G., Rinaldi M. G., Johnson T. R., Karp J. E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991 Oct 31;325(18):1274–1277. doi: 10.1056/NEJM199110313251803. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES